Farrell Simon Sells 81,313 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock

Trevi Therapeutics, Inc. (NASDAQ:TRVI) insider Farrell Simon sold 81,313 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the sale, the insider now directly owns 76,900 shares in the company, valued at approximately $519,075. This represents a 51.39 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Trevi Therapeutics Stock Performance

Shares of TRVI stock remained flat at $6.30 on Wednesday. The stock had a trading volume of 1,757,685 shares, compared to its average volume of 2,038,486. The stock has a market cap of $484.26 million, a PE ratio of -14.32 and a beta of 0.90. The stock’s fifty day moving average price is $4.22 and its 200 day moving average price is $3.56. Trevi Therapeutics, Inc. has a 1-year low of $2.30 and a 1-year high of $7.39.

Institutional Investors Weigh In On Trevi Therapeutics

A number of large investors have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. lifted its holdings in Trevi Therapeutics by 44.5% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock worth $43,939,000 after buying an additional 3,283,684 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Trevi Therapeutics in the 4th quarter valued at about $17,099,000. Vivo Capital LLC lifted its position in shares of Trevi Therapeutics by 116.3% during the fourth quarter. Vivo Capital LLC now owns 3,487,903 shares of the company’s stock worth $14,370,000 after purchasing an additional 1,875,000 shares during the last quarter. Woodline Partners LP grew its stake in Trevi Therapeutics by 429.9% in the fourth quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock worth $13,236,000 after purchasing an additional 2,606,370 shares in the last quarter. Finally, MPM Bioimpact LLC increased its holdings in Trevi Therapeutics by 101.2% in the fourth quarter. MPM Bioimpact LLC now owns 3,094,896 shares of the company’s stock valued at $12,751,000 after buying an additional 1,556,379 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on TRVI shares. Oppenheimer lifted their price target on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday. Needham & Company LLC increased their price target on shares of Trevi Therapeutics from $8.00 to $25.00 and gave the company a “buy” rating in a research report on Monday. Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the stock from $9.00 to $29.00 in a research report on Monday. HC Wainwright boosted their price target on Trevi Therapeutics from $7.50 to $12.50 and gave the company a “buy” rating in a report on Monday. Finally, D. Boral Capital reiterated a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research note on Friday, March 7th. Seven analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $15.94.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.